C. Verrier

发表

Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer.

N. Roodi, L. Bailey, W. Dupont, 1995, Journal of the National Cancer Institute.

Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans.

N. Roodi, L. Bailey, W. Dupont, 1998, Cancer research.

Microsatellite instability and loss of heterozygosity in breast cancer.

N. Roodi, F. Parl, C. Verrier, 1994, Cancer research.

Microsatellite instability and loss of heterozygosity in breast cancer.

N. Roodi, F. Parl, C. Verrier, 1994, Cancer research.

Yeast Screens Identify the RNA Polymerase II CTD and SPT5 as Relevant Targets of BRCA1 Interaction

D. D. Bailey, C. Blanchette, J. Olson, 2008, PloS one.

Is There a Role for ErbB Dual Kinase Inhibition

K. Blackwell, C. Verrier, 2007 .

High-mobility group (HMG) protein HMG-1 and TATA-binding protein-associated factor TAF(II)30 affect estrogen receptor-mediated transcriptional activation.

N. Roodi, L. Bailey, F. Parl, 1997, Molecular endocrinology.

Pathologic complete response (pCR) with weekly nanoparticle albumin bound (nab-P) plus carboplatin (C) followed by doxorubicin plus cyclophosphamide (AC) with concurrent bevacizumab (B) for triple-negative breast cancer (TNBC).

J. Sachdev, C. Verrier, M. Jahanzeb, 2013 .

Cardiotoxicity of Trastuzumab Treatment in African American Women and Older Women in the Non Trial Setting.

J. Sachdev, C. Verrier, M. Jahanzeb, 2009 .